Beximco Pharma GDRs back on London bourse

Trading in the Global Depository Receipts (GDRs) of Beximco Pharmaceuticals PLC on the London Stock Exchange (LSE) resumed on Friday after the exchange lifted a suspension imposed over delayed financial reporting.

Beximco Pharma is the only Bangladeshi company listed on the LSE, where it debuted in 2004.

Trading in its GDRs was suspended on January 2 this year, after the company failed to publish its audited financial statements for the year ended June 30, 2025, along with subsequent financial reports within the required timeframe.

Under LSE listing rules, a security that remains suspended for six consecutive months without the underlying issue being resolved is liable to be delisted. For Beximco Pharma, that deadline was due to fall on July 2, 2026.

Against that backdrop, foreign institutional and individual investors wrote to the Bangladesh Securities and Exchange Commission (BSEC), urging the regulator to take the necessary steps to prevent the GDRs from being delisted.

They also sought the support of the DSE Brokers Association of Bangladesh (DBA), according to a press release issued by the association yesterday.

The BSEC later allowed the company to hold a special board meeting to approve and publish its outstanding financial reports.

These included the third-quarter financial statements for the 2024-25 financial year, the audited annual report and the first, second and third-quarter reports for the 2025-26 financial year.

The move cleared the company’s reporting backlog, allowing the LSE to lift the suspension and resume trading in the GDRs from June 26.

The DBA thanked Finance and Planning Minister Amir Khosru Mahmud Chowdhury, Prime Minister’s Special Assistant for Investment and Capital Markets Tanvir Hani, BSEC Chairman Masud Khan, BSEC commissioners and officials, and the board and management of Beximco Pharma for their roles in resolving the issue.

Meanwhile, Beximco Pharma reported a net profit of Tk 699 crore for FY25, its highest annual earnings since listing on the stock market, driven by strong sales growth. Following the record performance, the board declared a 47.5 percent cash dividend for FY25, the largest cash payout in the company’s history.